



(51) International Patent Classification:

C07K 14/52 (2006.01) A61P 35/00 (2006.01)
A61K 38/00 (2006.01) A61P 37/04 (2006.01)
A61K 38/19 (2006.01)

(21) International Application Number:

PCT/US2023/072760

(22) International Filing Date:

23 August 2023 (23.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/373,436 24 August 2022 (24.08.2022) US

(71) Applicants: MONTEFIORE MEDICAL CENTER

[US/US]; 111 East 210th Street, Bronx, New York 10467 (US). ALBERT EINSTEIN COLLEGE OF MEDICINE [US/US]; 1300 Morris Park Avenue, Bronx, New York 10461 (US).

(72) Inventors: GUHA, Chandan; 111 East 210th Street,

Bronx, New York 10467 (US). ALMO, Steven; 1300 Morris Park Avenue, Bronx, New York 10461 (US). DUDEMPUDI, Phaneendra; 1300 Morris Park Avenue, Bronx, New York 10461 (US).

(74) Agent: HAN, Eunhee; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: FLT3 LIGAND BI-FUNCTIONAL MOLECULES FOR THROMBOPENIA AND ACUTE RADIATION SYNDROME




FIGURE 1

(57) Abstract: Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such polypeptides, expression vectors and cells comprising such nucleic acids, and methods of producing the polypeptides comprising a thrombopoietin domain and a Flt3 ligand domain. The administration of a fusion polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain to a subject may treat and reduce the symptoms of hematopoietic failure, including thrombopenia, and/or acute radiation syndrome.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*